U.S. President Donald Trump purchased shares in defense and technology firm Axon on February 10, a move that has drawn sharp criticism from ethics experts amid looming multi-billion-dollar government contracts.
The acquisition, valued between $1 million and $5 million, places the president in direct financial interest with a company that stands to benefit from federal defense spending under his administration.
The timing of the investment has intensified scrutiny over potential conflicts of interest.
Critics argue that the purchase creates an appearance of impropriety, particularly as Axon is positioned to secure significant government orders.
The revelation adds to ongoing debates about the separation of personal financial interests and official duties in the White House.
This development emerges against a backdrop of heightened geopolitical tensions.